| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2022 | 1426 | 4.510 |
Why?
|
| STAT3 Transcription Factor | 8 | 2021 | 80 | 3.250 |
Why?
|
| Neoplastic Stem Cells | 7 | 2020 | 74 | 2.220 |
Why?
|
| Telomerase | 4 | 2017 | 40 | 2.210 |
Why?
|
| Prostatic Neoplasms | 10 | 2024 | 794 | 1.970 |
Why?
|
| Colorectal Neoplasms | 6 | 2017 | 413 | 1.960 |
Why?
|
| Cell Proliferation | 19 | 2022 | 1149 | 1.930 |
Why?
|
| Receptor, erbB-2 | 5 | 2019 | 122 | 1.900 |
Why?
|
| Quercetin | 5 | 2024 | 41 | 1.730 |
Why?
|
| Cell Line, Tumor | 30 | 2022 | 2128 | 1.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2022 | 781 | 1.610 |
Why?
|
| Antineoplastic Agents | 12 | 2022 | 756 | 1.540 |
Why?
|
| Signal Transduction | 16 | 2021 | 1802 | 1.420 |
Why?
|
| Neoplasms | 9 | 2022 | 1033 | 1.380 |
Why?
|
| Tea | 4 | 2024 | 41 | 1.250 |
Why?
|
| Transforming Growth Factor beta | 3 | 2021 | 183 | 1.250 |
Why?
|
| STAT1 Transcription Factor | 2 | 2017 | 26 | 1.210 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2019 | 209 | 1.120 |
Why?
|
| Taxoids | 2 | 2016 | 36 | 1.080 |
Why?
|
| NF-kappa B | 4 | 2018 | 306 | 1.060 |
Why?
|
| Humans | 57 | 2022 | 34853 | 0.980 |
Why?
|
| Cell Movement | 8 | 2022 | 545 | 0.960 |
Why?
|
| Phosphorylation | 10 | 2019 | 878 | 0.960 |
Why?
|
| Lignans | 3 | 2024 | 21 | 0.930 |
Why?
|
| Furans | 3 | 2024 | 34 | 0.920 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 59 | 0.900 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 66 | 0.880 |
Why?
|
| Interleukin-6 | 3 | 2017 | 140 | 0.850 |
Why?
|
| Curcumin | 3 | 2020 | 66 | 0.840 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2021 | 325 | 0.830 |
Why?
|
| Chemokine CCL2 | 2 | 2020 | 82 | 0.780 |
Why?
|
| Exosomes | 1 | 2022 | 97 | 0.750 |
Why?
|
| Benzamides | 3 | 2017 | 76 | 0.730 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2019 | 49 | 0.690 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 117 | 0.670 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 198 | 0.670 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2020 | 245 | 0.670 |
Why?
|
| Female | 31 | 2022 | 19873 | 0.670 |
Why?
|
| Catechin | 2 | 2015 | 30 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 178 | 0.640 |
Why?
|
| Mice | 16 | 2024 | 5668 | 0.620 |
Why?
|
| Withanolides | 1 | 2017 | 8 | 0.620 |
Why?
|
| Lactic Acid | 2 | 2022 | 87 | 0.620 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 15 | 0.610 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 105 | 0.610 |
Why?
|
| Pyrans | 1 | 2017 | 9 | 0.610 |
Why?
|
| Smad4 Protein | 1 | 2017 | 6 | 0.610 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2017 | 39 | 0.600 |
Why?
|
| Drug Synergism | 5 | 2016 | 171 | 0.600 |
Why?
|
| Animals | 20 | 2024 | 14307 | 0.590 |
Why?
|
| HT29 Cells | 4 | 2017 | 40 | 0.590 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 29 | 0.580 |
Why?
|
| Mammography | 1 | 2018 | 176 | 0.570 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 48 | 0.570 |
Why?
|
| Glycolysis | 2 | 2022 | 66 | 0.570 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 211 | 0.560 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 203 | 0.560 |
Why?
|
| Haplotypes | 2 | 2014 | 152 | 0.560 |
Why?
|
| Flavonoids | 1 | 2016 | 78 | 0.550 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2020 | 30 | 0.540 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2024 | 53 | 0.530 |
Why?
|
| Alleles | 2 | 2013 | 284 | 0.520 |
Why?
|
| Gene Expression | 1 | 2018 | 639 | 0.520 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.510 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 282 | 0.500 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 74 | 0.490 |
Why?
|
| MicroRNAs | 6 | 2022 | 386 | 0.480 |
Why?
|
| Transcription Factors | 3 | 2020 | 653 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 107 | 0.470 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 446 | 0.460 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 12 | 0.450 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 336 | 0.440 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 480 | 0.430 |
Why?
|
| Phenotype | 4 | 2016 | 650 | 0.420 |
Why?
|
| Immunoprecipitation | 3 | 2017 | 126 | 0.420 |
Why?
|
| Obesity | 3 | 2020 | 965 | 0.410 |
Why?
|
| Disease Progression | 5 | 2020 | 580 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 465 | 0.400 |
Why?
|
| beta Catenin | 3 | 2017 | 46 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 247 | 0.400 |
Why?
|
| Apoptosis | 9 | 2022 | 1317 | 0.390 |
Why?
|
| DNA Methylation | 2 | 2013 | 301 | 0.390 |
Why?
|
| DNA | 1 | 2013 | 549 | 0.380 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 165 | 0.370 |
Why?
|
| Mice, Nude | 5 | 2020 | 323 | 0.370 |
Why?
|
| Caspase 8 | 1 | 2010 | 31 | 0.370 |
Why?
|
| Serpins | 1 | 2010 | 26 | 0.370 |
Why?
|
| Models, Biological | 3 | 2022 | 642 | 0.360 |
Why?
|
| CpG Islands | 1 | 2010 | 91 | 0.360 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 396 | 0.350 |
Why?
|
| Male | 15 | 2024 | 18870 | 0.330 |
Why?
|
| Tumor Burden | 2 | 2020 | 79 | 0.320 |
Why?
|
| Down-Regulation | 3 | 2015 | 420 | 0.300 |
Why?
|
| Middle Aged | 9 | 2018 | 9642 | 0.300 |
Why?
|
| Pyrazoles | 2 | 2017 | 80 | 0.300 |
Why?
|
| Neovascularization, Pathologic | 4 | 2022 | 122 | 0.290 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2017 | 22 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 242 | 0.290 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2019 | 71 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 445 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 984 | 0.280 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 161 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2017 | 157 | 0.270 |
Why?
|
| NIH 3T3 Cells | 2 | 2016 | 60 | 0.260 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 114 | 0.260 |
Why?
|
| Estrogen Receptor beta | 2 | 2015 | 37 | 0.260 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 23 | 0.260 |
Why?
|
| Los Angeles | 4 | 2015 | 368 | 0.260 |
Why?
|
| Up-Regulation | 3 | 2020 | 490 | 0.250 |
Why?
|
| Ethanol | 2 | 2016 | 188 | 0.250 |
Why?
|
| Ligands | 2 | 2023 | 317 | 0.250 |
Why?
|
| Cohort Studies | 3 | 2021 | 1422 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 430 | 0.240 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 391 | 0.240 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2015 | 22 | 0.240 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 790 | 0.230 |
Why?
|
| Cadherins | 2 | 2014 | 82 | 0.230 |
Why?
|
| Blotting, Western | 2 | 2017 | 834 | 0.230 |
Why?
|
| Community-Based Participatory Research | 3 | 2015 | 292 | 0.220 |
Why?
|
| Drug Design | 1 | 2023 | 154 | 0.220 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2022 | 9 | 0.210 |
Why?
|
| Muscle Proteins | 1 | 2022 | 48 | 0.210 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2011 | 18 | 0.200 |
Why?
|
| Metformin | 1 | 2022 | 64 | 0.200 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2020 | 93 | 0.190 |
Why?
|
| Glucose | 2 | 2022 | 217 | 0.190 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2022 | 87 | 0.190 |
Why?
|
| Animal Feed | 1 | 2020 | 42 | 0.190 |
Why?
|
| Proteins | 1 | 2023 | 352 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2020 | 122 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 200 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1056 | 0.190 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 26 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 605 | 0.190 |
Why?
|
| Genotype | 2 | 2014 | 641 | 0.190 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 65 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 1300 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 133 | 0.180 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2019 | 9 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 484 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 47 | 0.180 |
Why?
|
| Enzyme Activators | 1 | 2019 | 10 | 0.170 |
Why?
|
| S100 Proteins | 1 | 2019 | 12 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 137 | 0.170 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 145 | 0.170 |
Why?
|
| Inflammation | 2 | 2020 | 577 | 0.170 |
Why?
|
| Adult | 6 | 2015 | 11034 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 197 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2016 | 143 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
| Adipose Tissue | 1 | 2020 | 167 | 0.170 |
Why?
|
| Minority Health | 1 | 2019 | 81 | 0.170 |
Why?
|
| Nicotine | 1 | 2020 | 238 | 0.160 |
Why?
|
| Androgens | 2 | 2017 | 87 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 2 | 0.160 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 19 | 0.160 |
Why?
|
| Triazines | 1 | 2017 | 19 | 0.160 |
Why?
|
| Chromatin | 1 | 2019 | 164 | 0.160 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 88 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 122 | 0.150 |
Why?
|
| RNA, Messenger | 2 | 2013 | 1152 | 0.150 |
Why?
|
| Pyrroles | 1 | 2017 | 54 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 600 | 0.150 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.150 |
Why?
|
| Hyperinsulinism | 1 | 2016 | 17 | 0.150 |
Why?
|
| DNA Damage | 1 | 2019 | 341 | 0.150 |
Why?
|
| Pyrimidines | 1 | 2017 | 112 | 0.150 |
Why?
|
| Ubiquitination | 1 | 2017 | 54 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2015 | 727 | 0.150 |
Why?
|
| Fluorouracil | 1 | 2016 | 32 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2016 | 91 | 0.140 |
Why?
|
| Perception | 2 | 2015 | 183 | 0.140 |
Why?
|
| Survival Rate | 2 | 2015 | 310 | 0.140 |
Why?
|
| Cell Survival | 2 | 2017 | 818 | 0.140 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2015 | 18 | 0.140 |
Why?
|
| Receptors, Scavenger | 1 | 2015 | 13 | 0.140 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2015 | 31 | 0.140 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2015 | 26 | 0.130 |
Why?
|
| Chemokines, CXC | 1 | 2015 | 35 | 0.130 |
Why?
|
| Deoxyglucose | 1 | 2015 | 19 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2015 | 35 | 0.130 |
Why?
|
| Endothelin-1 | 1 | 2015 | 54 | 0.130 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 292 | 0.130 |
Why?
|
| Somatomedins | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 50 | 0.130 |
Why?
|
| Antibodies | 1 | 2015 | 135 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 964 | 0.130 |
Why?
|
| Breast | 1 | 2016 | 134 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2016 | 177 | 0.130 |
Why?
|
| 3T3 Cells | 1 | 2014 | 58 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2015 | 61 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 107 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 371 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 70 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 180 | 0.120 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 25 | 0.120 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2014 | 28 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2015 | 775 | 0.120 |
Why?
|
| Cyclic S-Oxides | 1 | 2013 | 2 | 0.120 |
Why?
|
| Lactation | 1 | 2014 | 38 | 0.120 |
Why?
|
| Minority Groups | 1 | 2019 | 537 | 0.120 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 18 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 65 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 145 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 162 | 0.120 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2013 | 2 | 0.120 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 43 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2016 | 250 | 0.120 |
Why?
|
| Carrier Proteins | 1 | 2015 | 287 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 162 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 366 | 0.110 |
Why?
|
| Transfection | 2 | 2010 | 496 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 570 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 164 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 608 | 0.110 |
Why?
|
| Vitamin D | 1 | 2013 | 176 | 0.100 |
Why?
|
| Menopause | 1 | 2011 | 54 | 0.100 |
Why?
|
| Prostate | 2 | 2024 | 136 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 287 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2010 | 49 | 0.090 |
Why?
|
| Morpholines | 1 | 2010 | 65 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2561 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 638 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2023 | 467 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 30 | 0.090 |
Why?
|
| Chromones | 1 | 2010 | 51 | 0.090 |
Why?
|
| Chemoprevention | 2 | 2024 | 34 | 0.090 |
Why?
|
| Risk Factors | 1 | 2018 | 3414 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 105 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2010 | 423 | 0.090 |
Why?
|
| Acetylation | 2 | 2019 | 94 | 0.090 |
Why?
|
| Prognosis | 2 | 2022 | 707 | 0.090 |
Why?
|
| Comorbidity | 1 | 2011 | 606 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2014 | 1961 | 0.080 |
Why?
|
| Acetaldehyde | 2 | 2016 | 10 | 0.070 |
Why?
|
| United States | 2 | 2019 | 3894 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 550 | 0.070 |
Why?
|
| Hormones | 1 | 2022 | 51 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 34 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2022 | 19 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2015 | 435 | 0.050 |
Why?
|
| Mecamylamine | 1 | 2020 | 14 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2021 | 37 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2024 | 897 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 114 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 1003 | 0.050 |
Why?
|
| Health Behavior | 2 | 2015 | 491 | 0.050 |
Why?
|
| Sirolimus | 1 | 2020 | 58 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 152 | 0.050 |
Why?
|
| Imidazoles | 1 | 2020 | 124 | 0.050 |
Why?
|
| Pyridines | 1 | 2020 | 113 | 0.050 |
Why?
|
| Adipokines | 1 | 2020 | 24 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2021 | 235 | 0.050 |
Why?
|
| Adipocytes | 1 | 2020 | 54 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 212 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 128 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2019 | 63 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 251 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 75 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 932 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 2333 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 649 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 133 | 0.040 |
Why?
|
| Hela Cells | 1 | 2019 | 344 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 158 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 177 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 53 | 0.040 |
Why?
|
| Nitriles | 1 | 2017 | 66 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 220 | 0.040 |
Why?
|
| Cytokines | 1 | 2020 | 569 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 416 | 0.030 |
Why?
|
| Estrogens | 1 | 2016 | 190 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 874 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 751 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 4012 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 5035 | 0.030 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 11 | 0.030 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 42 | 0.030 |
Why?
|
| Aged | 2 | 2015 | 6448 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 583 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 156 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 139 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1289 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 248 | 0.030 |
Why?
|
| Cell Death | 1 | 2013 | 260 | 0.030 |
Why?
|
| Genomics | 1 | 2013 | 201 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 41 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 40 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 968 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 859 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 209 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 166 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1023 | 0.020 |
Why?
|